



# Texas Medicaid/CHIP Vendor Drug Program

## Drug Utilization Criteria For Outpatient Use Guidelines

### Angiotensin-Converting Enzyme (ACE) Inhibitors

#### About

Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [\*]. The information contained is for the convenience of the public. The Texas Health and Human Services Commission is not responsible for any errors in transmission or any errors or omissions in the document.

#### Publication History

Revised December 2016; December 2014; March 2013; April 2011; March 2011; April 2008; June 2003; July 2002; September 2001; June 2001; June 2000; July 1999; June 1998; June 1997. Developed June 1996.

---

#### 1. Dosage [\*]

##### *Adults*

ACE inhibitors are FDA-approved for use in adults for diabetic nephropathy (captopril only), heart failure, hypertension, and improved survival/reduction of complications post myocardial infarction. Combination therapy is FDA-approved for use to manage hypertension. ACE inhibitors are available as monotherapy as well as combined with a calcium channel blocker or hydrochlorothiazide. Adult maximum daily doses for ACE inhibitors are summarized in Tables 1 and 2 for mono- and combination therapy, respectively. Dosages exceeding these recommendations will be reviewed.



**Texas Medicaid/CHIP Vendor Drug Program**  
**Drug Utilization Criteria For Outpatient Use Guidelines**  
**Angiotensin-Converting Enzyme (ACE) Inhibitors**

<b>Table 1: ACE Inhibitors as Monotherapy - Maximum Daily Adult Dose</b>		
<b>Drug</b>	<b>Dosage Form/Strength</b>	<b>Maximum Daily Dose</b>
benazepril (Lotensin®, generics)	<b>5 mg, 10 mg, 20 mg, 40 mg tablets</b>	hypertension: 80 mg*
captopril (generics)	<b>12.5 mg, 25 mg, 50 mg, 100 mg tablets</b>	diabetic nephropathy/proteinuria: 150 mg heart failure, hypertension: 450 mg post myocardial infarction: 150 mg
enalapril (Vasotec®, generics)  (Epaned®)	<b>2.5 mg, 5 mg, 10 mg, 20 mg tablets</b>  <b>1 mg/ml oral solution</b>	asymptomatic left ventricular dysfunction: 20 mg heart failure, hypertension: 40 mg
fosinopril (generics)	<b>10 mg, 20 mg, 40 mg tablets</b>	heart failure: 40 mg hypertension: 80 mg
lisinopril (Prinivil®, Zestril®, generics)  (Qbrelis®)	<b>2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg tablets</b>  <b>1 mg/ml oral solution</b>	acute myocardial infarction: 10 mg heart failure: 40 mg hypertension: 80 mg
moexipril (generics)	<b>7.5 mg, 15 mg tablets</b>	hypertension: 60 mg
perindopril (Aceon®, generics)	<b>2 mg, 4 mg, 8 mg tablets</b>	hypertension: 16 mg (elderly, renal function impairment: 8 mg ) myocardial infarction prophylaxis: 8 mg
quinapril (Accupril®, generics)	<b>5 mg, 10 mg, 20 mg, 40 mg tablets</b>	heart failure: 40 mg hypertension: 80 mg
ramipril (Altace®, generics)	<b>1.25 mg, 2.5 mg, 5 mg, 10 mg capsules</b>	heart failure (post myocardial infarction): 10 mg hypertension: 20 mg myocardial infarction prophylaxis: 10 mg
trandolapril (Mavik®, generics)	<b>1 mg, 2 mg, 4 mg tablets</b>	hypertension: 8 mg post myocardial infarction (heart failure, left ventricular dysfunction): 4 mg

\*Doses as high as 80 mg have provided increased response; however, experience with these higher dosages is limited.



**Texas Medicaid/CHIP Vendor Drug Program**  
**Drug Utilization Criteria For Outpatient Use Guidelines**  
**Angiotensin-Converting Enzyme (ACE) Inhibitors**

**Table 2: Adult Maximum Dosage Recommendations for ACE Inhibitor Combination Therapy**

<b>Drug</b>	<b>Dosage Form/Strength</b>	<b>Maximum Daily Dose</b>
amlodipine/benazepril (Lotrel®, generics)	<b>2.5 mg/10 mg, 5 mg/10 mg, 5 mg/20 mg, 5 mg/40 mg, 10 mg/20 mg, 10 mg/40 mg capsules</b>	hypertension: 10 mg/40 mg
benazepril/hydrochlorothiazide (Lotensin HCT®, generics)	<b>5 mg/6.25 mg, 10 mg/12.5 mg, 20 mg/12.5 mg, 20 mg/25 mg tablets</b>	hypertension: 20 mg/25 mg
captopril/hydrochlorothiazide (generics)	<b>25 mg/15 mg, 25 mg/25 mg, 50 mg/15 mg, 50 mg/25 mg tablets</b>	hypertension: 150 mg/50 mg
enalapril/hydrochlorothiazide (Vaseretic®, generics)	<b>5 mg/12.5 mg, 10 mg/25 mg tablets</b>	hypertension: 20 mg/50 mg
fosinopril/hydrochlorothiazide (generics)	<b>10 mg/12.5 mg, 20 mg/12.5 mg tablets</b>	<b>hypertension: 80 mg/50 mg</b>
lisinopril/hydrochlorothiazide (Zestoretic®, generics)	<b>10 mg/12.5 mg, 20 mg/12.5 mg, 20 mg/25 mg tablets</b>	hypertension: 80 mg/50 mg
moexipril/hydrochlorothiazide (generics)	<b>7.5 mg/12.5 mg, 15 mg/12.5 mg, 15 mg/25 mg tablets</b>	hypertension: 30 mg/50 mg
<b>perindopril/amlodipine (Prestalia®)</b>	<b>3.5 mg/2.5 mg, 7 mg/5 mg, 14 mg/10 mg tablets</b>	<b>hypertension: 14 mg/10 mg</b>
quinapril/hydrochlorothiazide (Accuretic®, generics)	<b>10 mg/12.5 mg, 20 mg/12.5 mg, 20 mg/25 mg tablets</b>	hypertension: 40 mg/25 mg
trandolapril/verapamil (Tarka®)	<b>1 mg/240 mg, 2 mg/180 mg, 2 mg/240 mg, 4 mg/240 mg extended-release tablets</b>	hypertension: 8 mg/240 mg

*Pediatrics*

Select ACE inhibitors are FDA-approved for use to manage hypertension in pediatric patients. Maximum recommended ACE inhibitor doses for pediatric patients are summarized in Table 3. Dosages exceeding these recommendations will be reviewed.

**Table 3: Maximum Recommended Doses for ACE inhibitors in Pediatric Patients**

<b>Drug</b>	<b>Maximum Daily Dosage</b>
benazepril	hypertension: 6 years of age and older: 0.6 mg/kg/day up to 40 mg/day
enalapril	hypertension: 1 month of age and older: 0.58 mg/kg/day up to 40 mg/day
fosinopril	hypertension: 6 to 16 years of age, > 50 kg: 40 mg daily > 16 years of age (> 50 kg): 80 mg daily
lisinopril	hypertension:



# Texas Medicaid/CHIP Vendor Drug Program

## Drug Utilization Criteria For Outpatient Use Guidelines

### Angiotensin-Converting Enzyme (ACE) Inhibitors

6 years of age and older: 0.6 mg/kg/day up to 40 mg/day
---

#### 2. Duration of Therapy

There is no basis for limiting ACE inhibitor therapy duration when utilized to manage hypertension, heart failure, and proteinuria associated with diabetic nephropathy, as these conditions require chronic treatment. **The 2016 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines support that ACE inhibitor use reduces cardiovascular morbidity and mortality in heart failure patients with reduced ejection fraction. Additionally, the ACC/AHA 2013 guidelines for ST-elevation myocardial infarction (STEMI) recommend immediate ACE inhibitor therapy within the first 24 hours) in patients with an anterior infarction, heart failure, or ejection fraction  $\leq 0.40$  who have no contraindications for ACE inhibitor use as well, as indefinite therapy with ACE inhibitors post-myocardial infarction for these patients. The ACC/AHA 2013 guidelines for unstable angina/non-STEMI patients recommend immediate ACE inhibitor therapy (within first 24 hours) in those with pulmonary congestion or left ventricular ejection fraction  $< 0.40$ , and no hypotension or contraindications to ACE inhibitor therapy. These guidelines also recommend prolonged use of ACE inhibitors in patients with heart failure, left ventricular ejection fraction  $< 0.40$ , hypertension, or diabetes mellitus without contraindications to ACE inhibitor therapy to reduce cardiovascular mortality.**

#### 3.\*Duplicative Therapy

The use of two or more ACE inhibitors concurrently is not justified. Additional therapeutic benefit is not realized when ACE inhibitors are used in combination. Patient profiles documenting the receipt of multiple ACE inhibitors will be reviewed.

#### 4.\* Drug-Drug Interactions

Patient profiles will be assessed to identify those drug regimens which may result in clinically significant drug-drug interactions. Drug-drug interactions considered clinically significant for ACE inhibitors are summarized in Table 4. Only those drug-drug interactions classified as clinical significance level 1/contraindicated or those considered life-threatening which have not yet been classified will be reviewed:



**Texas Medicaid/CHIP Vendor Drug Program**  
**Drug Utilization Criteria For Outpatient Use Guidelines**  
**Angiotensin-Converting Enzyme (ACE) Inhibitors**

**Table 4: ACE Inhibitor Drug-Drug Interactions**

<b>Target Drug</b>	<b>Interacting Drug</b>	<b>Interaction</b>	<b>Recommendation</b>	<b>Clinical Significance*</b>
ACE inhibitors	aliskiren	potential for additive hypotensive effects; increased hyperkalemia risk with this drug combination as both decrease serum aldosterone levels	administer drug combination cautiously; monitor serum potassium levels closely	moderate (DrugReax) 3-moderate (CP)
ACE inhibitors	angiotensin II receptor blockers	potential for enhanced pharmacologic/adverse effects (e.g., hypotension, hyperkalemia, changes in renal function) as both agents block renin-angiotensin-aldosterone system	avoid combination; if concurrent therapy necessary, monitor blood pressure, potassium and renal function and observe for adverse events	major (DrugReax) 2-major (CP)
ACE inhibitors	antidiabetic agents	potential for enhanced hypoglycemic effects due to improved insulin sensitivity by ACE inhibitors	closely monitor blood glucose levels; reduced antidiabetic doses may be necessary	moderate (DrugReax) 3-moderate (CP)
ACE inhibitors	azathioprine	increased risk of anemia, leukopenia with drug combination; mechanism unknown	avoid combination, if possible; if combined therapy necessary, monitor for myelosuppression	major (DrugReax) 2-major (CP)
lisinopril	clozapine	potential for increased serum clozapine levels and enhanced pharmacologic, adverse effects; lisinopril may decrease clozapine renal elimination through unknown mechanism	assess clinical response, monitor serum clozapine levels if drug combination utilized	3-moderate (CP)
ACE inhibitors	cyclosporine	increased risk of acute renal failure, hyperkalemia with drug combination due to ACE inhibition, which causes decreased angiotensin II and aldosterone	closely monitor renal function and serum potassium levels	moderate (DrugReax) 3-moderate (CP)
ACE inhibitors	entecavir	potential for increased entecavir serum levels and enhanced pharmacologic/adverse effects due to ACE inhibitor effects on renal function	monitor for increased adverse events if drug combination is administered	3-moderate (CP)
ACE inhibitors	eplerenone	increased risk of hyperkalemia as both agents decrease aldosterone levels	closely monitor serum potassium levels	2-major (CP)
ACE inhibitors	lithium	potential for increased serum lithium levels and enhanced pharmacologic, toxic effects, possibly due to decreased lithium clearance	avoid combination, if possible; if drug combination necessary, monitor serum lithium levels and observe for	moderate (DrugReax) 3-moderate (CP)



# Texas Medicaid/CHIP Vendor Drug Program

## Drug Utilization Criteria For Outpatient Use Guidelines

### Angiotensin-Converting Enzyme (ACE) Inhibitors

signs of lithium toxicity

**Table 4: ACE Inhibitor Drug-Drug Interactions (continued)**

Target Drug	Interacting Drug	Interaction	Recommendation	Clinical Significance*
ACE inhibitors	monoamine oxidase inhibitors	potential for additive hypotensive effects	monitor blood pressure closely, if drug combination utilized	3-moderate (CP)
ACE inhibitors	NSAIDs, salicylates, COX-2 inhibitors	potential for decreased antihypertensive effects, increased renal impairment risk (especially in patients dependent on renal prostaglandins for perfusion), with combined therapy due to inhibition of prostaglandin synthesis	monitor blood pressure, renal function, and clinical status if drug combination utilized; low-dose aspirin less likely to reduce ACE inhibitor antihypertensive, cardioprotective effects	moderate (DrugReax) 3-moderate (CP)
ACE inhibitors	potassium-sparing diuretics, potassium salts	ACE inhibitors reduce aldosterone concentrations, resulting in increased potassium concentrations; increased hyperkalemia risk with drug combination due to additive pharmacologic effects	monitor serum potassium levels and signs/symptoms of hyperkalemia if drug combination administered; patients with renal failure, diabetes, advanced age may be at increased risk; use combination cautiously in heart failure patients	major (DrugReax) 2-major (CP)
ACE inhibitors	pregabalin	combined therapy may increase risk of developing life-threatening angioedema with respiratory compromise	observe patients closely if drug combination utilized	2-major (CP)
<b>ACE inhibitors</b>	<b>sacubitril/valsartan (Entresto®)</b>	<b>concurrent administration may result in angioedema due to inhibition of bradykinin degradation</b>	<b>avoid drug combination; monitor blood pressure, renal function, and electrolytes if combined therapy is utilized</b>	<b>contraindicated (DrugReax) 1-contraindicated (CP)</b>
ACE inhibitors	trimethoprim	co-administration may increase risk of additive hyperkalemia due to decreased aldosterone synthesis by ACE inhibitor and potassium-sparing effect on distal nephron by trimethoprim	monitor serum potassium levels and monitor patients for signs/symptoms of hyperkalemia if drug combination administered	moderate (DrugReax) 2-major (CP)



## Texas Medicaid/CHIP Vendor Drug Program

### Drug Utilization Criteria For Outpatient Use Guidelines

#### Angiotensin-Converting Enzyme (ACE) Inhibitors

**Table 4: ACE Inhibitor Drug-Drug Interactions (continued)**

Target Drug	Interacting Drug	Interaction	Recommendation	Clinical Significance*
verapamil	flibanserin (Addyi®)	verapamil (CYP3A4 inhibitor) and flibanserin (CYP3A4 substrate) administered concurrently may result in increased serum flibanserin levels with resultant severe hypotension, syncope, sedation	avoid combined use; if adjunctive use necessary, discontinue CYP3A4 inhibitor for at least 2 weeks before initiating/reinitiating flibanserin therapy, or discontinue flibanserin at least 2 days before starting/restarting CYP3A4 inhibitor therapy	contraindicated (DrugReax) 1-severe (CP)
verapamil	colchicine	colchicine is p-glycoprotein (P-gp) and CYP3A4 substrate; adjunctive use may result in increased colchicine serum concentrations and enhanced pharmacologic/adverse effects due to P-gp and CYP3A4 inhibition by verapamil	avoid concurrent use; if combined use necessary, observe for serious colchicine adverse effects, including neuromuscular toxicity, and adjust colchicine dosages	contraindicated (DrugReax) 2-major (CP)
verapamil	dofetilide (Tikosyn®)	concomitant administration may result in increased cardiotoxicity risk (e.g., torsades de pointes, QT interval prolongation, cardiac arrest) due to increased dofetilide absorption/serum levels	combined use is contraindicated	contraindicated (DrugReax) 1-severe (CP)

\*CP = Clinical Pharmacology

#### REFERENCES

1. DRUGDEX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com.libproxy.uthscsa.edu>. **Accessed December 5<sup>th</sup>, 2016.**
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2016. Available at: <http://www.clinicalpharmacology.com>. **Accessed December 7<sup>th</sup>, 2016.**





## Texas Medicaid/CHIP Vendor Drug Program

### Drug Utilization Criteria For Outpatient Use Guidelines Angiotensin-Converting Enzyme (ACE) Inhibitors

3. **Facts and Comparisons eAnswers [database online].** Hudson, Ohio: Wolters Kluwer Clinical Drug Information, Inc.;2016. Available at: <http://eanswers.factsandcomparisons.com.ezproxy.lib.utexas.edu/>. Accessed December 5<sup>th</sup>, 2016.
4. **AHFS Drug Information 2016.** Jackson, WY: Teton Data Systems, **Version 8.8.1, 2015.** Stat!Ref Electronic Medical Library. Available at: <http://online.statref.com.libproxy.uthscsa.edu/>. Accessed December 5<sup>th</sup>, 2016.
5. Benazepril/hydrochlorothiazide (Lotensin HCT®) package insert. Validus Pharmaceuticals, **September 2015.**
6. Quinapril/hydrochlorothiazide (Accuretic®) package insert. Pfizer, **October 2015.**
7. Enalapril oral solution (Epaned®) package insert. Silvergate Pharmaceuticals, Inc., **January 2016.**
8. **Lisinopril oral solution (Qbrelis®) package insert.** Silvergate Pharmaceuticals, Inc., **July 2016.**
9. **Perindopril/amlodipine tablets (Prestalia®) package insert.** Symplmed Pharmaceuticals, **July 2015.**
10. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults. Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520.
11. **Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation. 2016;134:e282–e293. DOI: 10.1161/CIR.0000000000000435.**
12. **Anderson JL, Adams CD, Antman EM, et al. 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:e663–e828.**
13. O’Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:e78–e140.
14. Reeder GS. Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial infarction: recommendations for use. In: UpToDate, Post TW (Ed), UpToDate, Waltham, MA. **(Accessed on December 5<sup>th</sup>, 2016.)**
15. Hoogwerf BJ. Renin–angiotensin system blockade and cardiovascular and renal protection. Am J Cardiol. 2010;105[suppl]:30A–35A.
16. Pregabalin (Lyrica®) package insert. Pfizer, **March 2016.**
17. DRUG-REAX® System (electronic version). Truven Health Analytics, Greenwood Village, Colorado, USA. Available at: <http://www.micromedexsolutions.com.libproxy.uthscsa.edu>. Accessed December 7<sup>th</sup>, 2016.

#### Prepared by

- Drug Information Service, the University of Texas Health Science Center at San Antonio.
- The College of Pharmacy, the University of Texas at Austin.